Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Giorgio Antonucci, Enrico Girardi, Alessandro Cozzi-Lepri, Maria Rosaria Capobianchi, Andrea De Luca, Massimo Puoti, Enzo Petrelli, Giuseppe Carnevale, Giuliano Rizzardini, Paolo Antonio Grossi, Paolo Viganò, Maria Cristina Moioli, Fabrizio Carletti, Mariacarmela Solmone, Giuseppe Ippolito, Antonella D Arminio Monforte

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

BACKGROUND: The roles of hepatitis C virus (HCV) viremia and HCV genotype in the immune response to highly active antiretroviral therapy (HAART) are poorly understood. Our aim was to assess the CD4+ cell count recovery after HAART in human immunodeficiency virus (HIV)-infected patients with HCV viremia and HIV-infected patients who tested negative for HCV antibody (HCV-Ab). We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype. METHODS: The analysis focused on 1219 HCV-Ab-negative patients and 284 HCV-viremic patients from a cohort of HIV-infected subjects that includes persons who were antiretroviral naive before initiating HAART after cohort enrollment. HCV RNA load and HCV genotype were determined in plasma specimens obtained and stored during the 6-month period preceding the initiation of HAART. RESULTS: The chance of achieving a CD4+ cell count increase of > or = 100 cells/microL from the pre-HAART level tended to be poorer in HCV-viremic patients than in patients who tested negative for HCV-Ab (adjusted relative hazard [RH], 0.82; 95% confidence interval [CI], 0.66-1.01; P = .06). In contrast, a comparison of patients who had a HCV RNA load >1 x 10(6) IU/mL with patients who had a HCV RNA load of 5-1 x 10(6) IU/mL revealed no significant association between HCV RNA load and achievement of an increased CD4+ cell count (adjusted RH, 0.97; 95% CI, 0.75-1.27; P = .83). There was no clear association between HCV genotype and the probability of achieving a CD4+ cell count increase. CONCLUSIONS: An association between the presence of HCV-Ab and immune reconstitution after HAART has been shown elsewhere. Results of our large, prospective study support a direct role of HCV viremia in the CD4+ cell count response to HAART. Moreover, our results underline the fact that, in individuals coinfected with HIV and HCV, the goal of treating HCV infection is to eradicate HCV, to both slow the rate of HCV progression and limit potential interference with the response to HAART.

Original languageEnglish
JournalClinical Infectious Diseases
Volume40
Issue number12
Publication statusPublished - 2005

Fingerprint

Viremia
Highly Active Antiretroviral Therapy
Hepacivirus
Genotype
HIV
CD4 Lymphocyte Count
RNA
Confidence Intervals
Hepatitis C Antibodies

Cite this

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. / Antonucci, Giorgio; Girardi, Enrico; Cozzi-Lepri, Alessandro; Capobianchi, Maria Rosaria; De Luca, Andrea; Puoti, Massimo; Petrelli, Enzo; Carnevale, Giuseppe; Rizzardini, Giuliano; Grossi, Paolo Antonio; Viganò, Paolo; Moioli, Maria Cristina; Carletti, Fabrizio; Solmone, Mariacarmela; Ippolito, Giuseppe; Monforte, Antonella D Arminio.

In: Clinical Infectious Diseases, Vol. 40, No. 12, 2005.

Research output: Contribution to journalArticle

Antonucci, G, Girardi, E, Cozzi-Lepri, A, Capobianchi, MR, De Luca, A, Puoti, M, Petrelli, E, Carnevale, G, Rizzardini, G, Grossi, PA, Viganò, P, Moioli, MC, Carletti, F, Solmone, M, Ippolito, G & Monforte, ADA 2005, 'Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.', Clinical Infectious Diseases, vol. 40, no. 12.
Antonucci, Giorgio ; Girardi, Enrico ; Cozzi-Lepri, Alessandro ; Capobianchi, Maria Rosaria ; De Luca, Andrea ; Puoti, Massimo ; Petrelli, Enzo ; Carnevale, Giuseppe ; Rizzardini, Giuliano ; Grossi, Paolo Antonio ; Viganò, Paolo ; Moioli, Maria Cristina ; Carletti, Fabrizio ; Solmone, Mariacarmela ; Ippolito, Giuseppe ; Monforte, Antonella D Arminio. / Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. In: Clinical Infectious Diseases. 2005 ; Vol. 40, No. 12.
@article{f7ecdb033231418e9072f0383191ea58,
title = "Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.",
abstract = "BACKGROUND: The roles of hepatitis C virus (HCV) viremia and HCV genotype in the immune response to highly active antiretroviral therapy (HAART) are poorly understood. Our aim was to assess the CD4+ cell count recovery after HAART in human immunodeficiency virus (HIV)-infected patients with HCV viremia and HIV-infected patients who tested negative for HCV antibody (HCV-Ab). We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype. METHODS: The analysis focused on 1219 HCV-Ab-negative patients and 284 HCV-viremic patients from a cohort of HIV-infected subjects that includes persons who were antiretroviral naive before initiating HAART after cohort enrollment. HCV RNA load and HCV genotype were determined in plasma specimens obtained and stored during the 6-month period preceding the initiation of HAART. RESULTS: The chance of achieving a CD4+ cell count increase of > or = 100 cells/microL from the pre-HAART level tended to be poorer in HCV-viremic patients than in patients who tested negative for HCV-Ab (adjusted relative hazard [RH], 0.82; 95{\%} confidence interval [CI], 0.66-1.01; P = .06). In contrast, a comparison of patients who had a HCV RNA load >1 x 10(6) IU/mL with patients who had a HCV RNA load of 5-1 x 10(6) IU/mL revealed no significant association between HCV RNA load and achievement of an increased CD4+ cell count (adjusted RH, 0.97; 95{\%} CI, 0.75-1.27; P = .83). There was no clear association between HCV genotype and the probability of achieving a CD4+ cell count increase. CONCLUSIONS: An association between the presence of HCV-Ab and immune reconstitution after HAART has been shown elsewhere. Results of our large, prospective study support a direct role of HCV viremia in the CD4+ cell count response to HAART. Moreover, our results underline the fact that, in individuals coinfected with HIV and HCV, the goal of treating HCV infection is to eradicate HCV, to both slow the rate of HCV progression and limit potential interference with the response to HAART.",
author = "Giorgio Antonucci and Enrico Girardi and Alessandro Cozzi-Lepri and Capobianchi, {Maria Rosaria} and {De Luca}, Andrea and Massimo Puoti and Enzo Petrelli and Giuseppe Carnevale and Giuliano Rizzardini and Grossi, {Paolo Antonio} and Paolo Vigan{\`o} and Moioli, {Maria Cristina} and Fabrizio Carletti and Mariacarmela Solmone and Giuseppe Ippolito and Monforte, {Antonella D Arminio}",
year = "2005",
language = "English",
volume = "40",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

AU - Antonucci, Giorgio

AU - Girardi, Enrico

AU - Cozzi-Lepri, Alessandro

AU - Capobianchi, Maria Rosaria

AU - De Luca, Andrea

AU - Puoti, Massimo

AU - Petrelli, Enzo

AU - Carnevale, Giuseppe

AU - Rizzardini, Giuliano

AU - Grossi, Paolo Antonio

AU - Viganò, Paolo

AU - Moioli, Maria Cristina

AU - Carletti, Fabrizio

AU - Solmone, Mariacarmela

AU - Ippolito, Giuseppe

AU - Monforte, Antonella D Arminio

PY - 2005

Y1 - 2005

N2 - BACKGROUND: The roles of hepatitis C virus (HCV) viremia and HCV genotype in the immune response to highly active antiretroviral therapy (HAART) are poorly understood. Our aim was to assess the CD4+ cell count recovery after HAART in human immunodeficiency virus (HIV)-infected patients with HCV viremia and HIV-infected patients who tested negative for HCV antibody (HCV-Ab). We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype. METHODS: The analysis focused on 1219 HCV-Ab-negative patients and 284 HCV-viremic patients from a cohort of HIV-infected subjects that includes persons who were antiretroviral naive before initiating HAART after cohort enrollment. HCV RNA load and HCV genotype were determined in plasma specimens obtained and stored during the 6-month period preceding the initiation of HAART. RESULTS: The chance of achieving a CD4+ cell count increase of > or = 100 cells/microL from the pre-HAART level tended to be poorer in HCV-viremic patients than in patients who tested negative for HCV-Ab (adjusted relative hazard [RH], 0.82; 95% confidence interval [CI], 0.66-1.01; P = .06). In contrast, a comparison of patients who had a HCV RNA load >1 x 10(6) IU/mL with patients who had a HCV RNA load of 5-1 x 10(6) IU/mL revealed no significant association between HCV RNA load and achievement of an increased CD4+ cell count (adjusted RH, 0.97; 95% CI, 0.75-1.27; P = .83). There was no clear association between HCV genotype and the probability of achieving a CD4+ cell count increase. CONCLUSIONS: An association between the presence of HCV-Ab and immune reconstitution after HAART has been shown elsewhere. Results of our large, prospective study support a direct role of HCV viremia in the CD4+ cell count response to HAART. Moreover, our results underline the fact that, in individuals coinfected with HIV and HCV, the goal of treating HCV infection is to eradicate HCV, to both slow the rate of HCV progression and limit potential interference with the response to HAART.

AB - BACKGROUND: The roles of hepatitis C virus (HCV) viremia and HCV genotype in the immune response to highly active antiretroviral therapy (HAART) are poorly understood. Our aim was to assess the CD4+ cell count recovery after HAART in human immunodeficiency virus (HIV)-infected patients with HCV viremia and HIV-infected patients who tested negative for HCV antibody (HCV-Ab). We also aimed to assess whether the response to HAART in these patients varied according to HCV genotype. METHODS: The analysis focused on 1219 HCV-Ab-negative patients and 284 HCV-viremic patients from a cohort of HIV-infected subjects that includes persons who were antiretroviral naive before initiating HAART after cohort enrollment. HCV RNA load and HCV genotype were determined in plasma specimens obtained and stored during the 6-month period preceding the initiation of HAART. RESULTS: The chance of achieving a CD4+ cell count increase of > or = 100 cells/microL from the pre-HAART level tended to be poorer in HCV-viremic patients than in patients who tested negative for HCV-Ab (adjusted relative hazard [RH], 0.82; 95% confidence interval [CI], 0.66-1.01; P = .06). In contrast, a comparison of patients who had a HCV RNA load >1 x 10(6) IU/mL with patients who had a HCV RNA load of 5-1 x 10(6) IU/mL revealed no significant association between HCV RNA load and achievement of an increased CD4+ cell count (adjusted RH, 0.97; 95% CI, 0.75-1.27; P = .83). There was no clear association between HCV genotype and the probability of achieving a CD4+ cell count increase. CONCLUSIONS: An association between the presence of HCV-Ab and immune reconstitution after HAART has been shown elsewhere. Results of our large, prospective study support a direct role of HCV viremia in the CD4+ cell count response to HAART. Moreover, our results underline the fact that, in individuals coinfected with HIV and HCV, the goal of treating HCV infection is to eradicate HCV, to both slow the rate of HCV progression and limit potential interference with the response to HAART.

UR - http://www.scopus.com/inward/record.url?scp=33644519208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644519208&partnerID=8YFLogxK

M3 - Article

VL - 40

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -